REVIEW article

Front. Oncol., 31 October 2024

Sec. Cancer Immunity and Immunotherapy

Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1467898

Landscape of targeted therapies for lung squamous cell carcinoma

  • 1. Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei, China

  • 2. Institude of Experimental Immunology, University Clinic of Rheinische Friedrich-Wihelms-University, Bonn, Germany

Abstract

Lung cancer, a common type of malignant neoplasm, has seen significant advancements in the treatment of lung adenocarcinoma (LUAD). However, the management of lung squamous cell carcinoma (LSCC) continues to pose challenges. Traditional treatment methods for LSCC encompass surgical resection, chemotherapy, and radiotherapy. The introduction of targeted therapy and immunotherapy has greatly benefited LSCC patients, but issues such as limited immune response rates and adverse reactions persist. Therefore, gaining a deeper comprehension of the underlying mechanisms holds immense importance. This review provides an in-depth overview of classical signaling pathways and therapeutic targets, including the PI3K signaling pathway, CDK4/6 pathway, FGFR1 pathway and EGFR pathway. Additionally, we delve into alternative signaling pathways and potential targets that could offer new therapeutic avenues for LSCC. Lastly, we summarize the latest advancements in targeted therapy combined with immune checkpoint blockade (ICB) therapy for LSCC and discuss the prospects and challenges in this field.

1 Introduction

Lung cancer, a leading cause of cancer-related deaths worldwide (), is commonly classified into small-cell and non-small-cell subtypes (). Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases, with lung squamous cell carcinoma (LSCC) making up around 30% of them (). Smoking history, prolonged exposure to harmful substances, and familial genetic factors significantly contribute to the risk of lung cancer (–). Patients diagnosed with lung adenocarcinoma (LUAD) often benefit more from targeted therapy and immunotherapy than those with LSCC (). Operable mutations are rarely detected in patients with LSCC, resulting in limited treatment options (). Currently, the primary treatments for LSCC encompass surgical resection, chemotherapy, radiotherapy, targeted therapy, and immunotherapy (, , ). The standard treatment of early and middle-stage LSCC is primarily surgical treatment, supplemented by radiotherapy and chemotherapy, and the advanced treatment is mainly chemotherapy. However, surgical resection is often unfeasible for advanced LSCC cases (), and chemotherapy and radiotherapy can frequently lead to toxicity and drug resistance (, ). As an emerging approach in LSCC therapy, targeted therapy holds promise in improving patient survival rates and quality of life by inhibiting specific signaling pathways involved in cancer cell growth. Prominent pathway alterations, such as phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), cell cycle protein-dependent kinases 4 and 6 (CDK4/6), and rat sarcoma (RAS) pathways, have been observed. While treatment options for the two subtypes of NSCLC, namely LSCC and LUAD, were previously similar (), LSCC exhibits a higher prevalence of certain mutated genes, including tumor protein p53, glutamate receptor, metabotropic 8, Erb-B2 receptor tyrosine kinase 4, Kelch-like ECH-associated protein 1 (KEAP1), and mucin 16 (). However, a single targeted therapeutic approach still presents certain challenges owing to drug resistance and tumor heterogeneity.

Immunotherapy treatment for LSCC shows potential benefits, particularly in histological and mutational states (, ). Immune checkpoints, such as programmed death receptors and their ligands, naturally regulate the immune system to prevent overreaction and autoimmune diseases (). However, tumor cells often exploit programmed death ligands on their surface to bind to programmed death acceptors, impeding the function of T cells, thereby evading immune surveillance (, ). Immune checkpoint blockade (ICB) therapy stimulates the immune system to re-recognize tumor cells and increase its aggression by inhibiting the binding of tumor cells to programmed death receptors and their ligands (, ). Current ICB first- and second-line therapies for advanced LSCC include programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors (). Despite these advances, further comprehensive studies are required to address issues such as the search for novel medicines, immune tolerance management, and hazardous side effects (, ). ICB therapy can cause unique toxicity by enhancing immune response, consequently inducing immune-related adverse events (). Additionally, many patients with LSCC develop immune escape owing to the human leukocyte antigen gene mutations (). Combining immunotherapy with other therapies, including targeted therapy, may offer a reliable solution. Some classical signaling pathways, such as PI3K and CDK4/6, are associated with a tumor mutational burden (TMB) state. Novel targets such as nuclear receptor-binding SET domain protein 3 (NSD3), lysine methyltransferase 2 D (KMT2D), and ubiquitin-specific peptidase 28 (USP28), are related to tumor microenvironment (TME) and immune cells. A recent study involving 1008 patients with LUAD and LSCC suggests that identifying elevated PD-L1 expression levels could effectively guide targeted therapy. This is because PD-L1 is more prevalent in men, smokers, and squamous cell carcinoma tumors with a maximum diameter >3 cm, poorly differentiated, and/or high tumor node metastasis stage ().

Future LSCC research will continue to focus on individualized treatment plans (). This review summarizes the current knowledge of potential targetable gene alterations in LSCC, and considers repurposing some targets effective against other cancers, including LUAD. Considering the complex genome of patients with LSCC, we further discuss the possibility of multi-target combination therapy and combining immunotherapy with targeted therapy to improve the efficacy of LSCC treatment. We anticipate more advances in LSCC therapy, which will benefit the clinical outcomes of patients by broadening the pool of possible therapeutic targets, increasing drug selectivity, and implementing treatment approaches like targeted therapy in conjunction with immunotherapy or multi-target combination therapy.

2 Targeting classical targets in LSCC

Previous studies have shown that patients with LSCC exhibit numerous genetic alterations, affecting various signaling pathways. The most commonly mutated genes in lung squamous carcinoma include phosphatase and tensin homolog (PTEN), EGFR, cyclin dependent kinase inhibitor 2A, and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) (, ). This section introduces several previously identified classical targets, along with their associated developments, paving the way for new targets and therapeutic strategies (Figure 1).

Figure 1

2.1 PI3K

Research has identified overactivation of the PI3K/AKT signaling pathway as a prevalent etiology among cancers (31). This pathway is disrupted in 68% of LSCC samples (32).

PI3K is divided into three main classes. Class I PI3K, which is strongly associated with cancer (33), is comprised of the catalytic subunit p110 (with four subtypes: α, β, γ, and δ) and regulatory subunit p85 (34, 35). P110α directly binds to the RAS gene or recruits the p85 subunit to the tyrosine phosphorylated receptor and receptor-associated adaptor proteins, signaling downstream plasma membrane-associated tyrosine kinase (36).

The primary manifestations of PI3K signal distortion in LSCC are PIK3CA amplification, PIK3CA mutation, and PTEN loss (37, 38). Tumor suppressor PTEN activation impacts the negative feedback mediating PI3K, significantly inhibiting tumor cell growth and invasion along with the activity of focal adhesion kinase (39, 40). PIK3CA mutations often co-mutate with other oncogenes such as EGFR, RAS, TP53, and so on (41), making it difficult to accurately target them with existing therapies (42). Furthermore, several clinical studies and experimental investigations have yielded negative results. When PI3K is inhibited, adaptive overexpression occurs in several compensatory pathways, leading to drug resistance (43). Furthermore, hyperglycemia has been reported in some patients treated with PI3K/AKT inhibitors (44), possibly due to the promotion of insulin-stimulated glucose uptake and storage by this pathway. Although the PTEN–PI3K axis has been established in LSCC studies, this pathway also plays a role in many normal cellular functions, while mutation-specific inhibitors remain unavailable. Ultimately, we need to deepen our understanding of PI3K’s function in cancer environment and enhance the durability and specificity of relevant treatments.

2.2 EGFR

The erbB-1 gene encodes EGFR, a transmembrane protein crucial for cell functions such as proliferation, growth, apoptosis, repair, and survival (45, 46). Mutations in the EGFR tyrosine kinase region, mainly in exons 18–21, are strongly associated with a subset of patients with LSCC, particularly women and non-smokers (, 47, 48). Roughly half of patients with lung cancer exhibit EGFR mutations, with a notable increase in EGFR protein expression in LSCC compared with LUAD (49, 50). Furthermore, the mRNA abundance of the five EGFR ligands strongly correlates with EGFR-amplified LSCC cohorts, but no increase in EGFR pathway activity was observed (51). This suggests that EGFR ligand abundance is a more accurate indicator of EGFR inhibitor responsiveness in these patients.

Currently, EGFR-tyrosine kinase inhibitors (TKI) are a key therapeutic option for patients with LSCC and EGFR-activating mutations, significantly improving clinical outcomes (). However, owing to an altered EGFR signaling pathway and activation of abnormal bypass pathway, acquired resistance of 1st, 2nd, and 3rd generation EGFR-TKI remains inevitable (52, 53). For EGFR-mutated patients with NSCLC who progress after EGFR-TKI treatment, a combination with immune checkpoint inhibitors (ICIs), chemotherapy, and anti-vascularization offers the greatest survival benefit, according to a statistical analysis of 2,085 patients in 17 studies (54).

2.3 FGFR

The FGFR family is key in tissue development and cancer progression, forming complexes with fibroblast growth factor (FGF) which activates several downstream signal transduction pathways (55, 56). Dysregulation of FGFR expression can contribute to tumor cell proliferation, survival, resistance, and immune escape (56), with LSCC showing higher FGFR1 levels than LUAD (37, 57).

FGF regulates the FGFR signaling pathway, maintaining tissue homeostasis, promoting repair and development, and influencing cell proliferation, differentiation, migration, survival, and angiogenesis (58, 59). FGF19 is crucial in prostate and breast cancer progression as it binds to the FGFR4 and Klotho complexes to initiate downstream signaling, significantly affecting LSCC development and proliferation (60–63). GLI family zinc finger 2 (GLI2), a downstream effector of FGF19, is induced by the TGF-B/SMAD pathway and is significant in promoting cancer metastasis (64). High FGF19 expression is associated with poor outcomes in LSCC, driving cell invasion through GLI2-mediated epithelial-mesenchymal transition (EMT) (65). As a result, therapeutic strategies that focus on the positive feedback loop of FGF19-GLI2 may be effective in treating LSCC.

FGFR emerges as a potential therapeutic target for LSCC (66). Current targeted therapeutics of FGFR include ortho-binding inhibitors, allosteric inhibitors, ligand traps, and small-molecule kinase inhibitors (67). FGFR1 amplification, the most common FGFR mutation affecting approximately 20% of patients with LSCC (51), has not been proven to be a reliable predictor in therapeutic trials (57, 68). Furthermore, the complex action mechanism of NSCLC and the uncertain origins of FGFR1 mutations warrant further research to understand or determine FGFR1 signaling in LSCC pathophysiology.

2.4 ALK

Anaplastic lymphoma kinase (ALK) regulates the function of the frontal cortex and hippocampus of the adult brain as well as influences tumor cell cycle control, thus impacting tumor transformation (69). Although unessential for normal growth and development, ALK's activation of signaling pathways, such as Janus kinase/signal transducer of activation, mitogen-activated protein kinase (MAPK), PI3K/AKT, and mitogen-activated protein kinase kinase (MEK) 5-extracellular signal-regulated kinase (ERK) 5, underscores its essential role in cell proliferation, differentiation, and apoptosis inhibition, making it a potential target for cancer therapy (70).

ALK rearrangements, particularly its fusion with echinodermal microtubule-associated protein-like 4, are common in NSCLC, with ALK mutations present in approximately 5% of cases, mostly patients with LUAD (71–74). Despite this, the large NSCLC patient population keeps ALK as a significant therapeutic target. Targeted therapy with TKIs, including crizotinib (first-generation), alectinib, ceritinib, ansatinib, brigatinib (second-generation), and loratinib (third-generation), has been developed for ALK-rearranged NSCLC (75–77). However, challenges including drug resistance and toxicity require further research and the development of new treatments (78).

2.5 RAS

When the RAS proteins are activated, they initiate several downstream signaling pathways, such as the PI3K/AKT/mTOR network, RAF/MEK/ERK pathway, and RalEGF/Ral route (79, 80). The dysregulation of the RAF/MEK/ERK signaling pathway is linked to tumor growth (81). The PI3K/AKT/mTOR pathway is associated with tumor pathologies (82). Despite initial challenges of “undruggable”, targeted allele-specific inhibitors of RAS, such as Kirsten rat sarcoma virus (KRAS)-G12C targeting drugs, have been developed, potentially changing the treatment landscape for RAS-driven tumors (83).

KRAS mutations are a frequent genetic cause of NSCLC, especially LUAD, but are rare in LSCC, with KRAS mutation rates reported between 1 and 7% in LSCC (84). Controversies exist regarding the presence of KRAS mutations in LSCC; some data suggest that KRAS mutations may be misclassified as LUAD or adenosquamous carcinoma. However, the persistence of KRAS mutations suggests that KRAS mutant LSCC is likely to exist, and future evidence may provide further clarification (85).

2.6 MEK

MEK is an important downstream component of the RAS with two main isoforms: MEK1 and MEK2 (86). It functions by specifically phosphorylating tyrosine and threonine residues in the activation loops of ERK1/2, playing a role in the RAS/RAF/MEK/ERK pathway (87). The MEK mutations are less common in patients (88). However, due to the importance of the RAF/MEK/ERK pathway, MEK is considered a potential target for new cancer therapies. For LSCC patients with V-raf murine sarcoma viral oncogene homolog B (BRAF) or KRAS mutations, monotherapy or combination therapy with MEK inhibitors, including trametinib, binimetinib, selumetinib, and cobimetinib, approved by the United States Food and Drug Administration (FDA), may be a promising treatment strategy. Compared with MEK inhibitor monotherapy, MEK inhibitor combination therapy demonstrates better therapeutic efficacy and less toxic side effects. The clinical efficacy requires further validation (89–91).

2.7 CDK4/6

CDK4/6 are key mediators for cell cycle transition from the G1 to the S phase (92). They contribute to the CDK-activated kinase complex phosphorylation of a CDK4/6 complex and activate cyclin D (93). Then, it phosphorylates the retinoblastoma, preventing it from repressing the E2F family of transcription factors, thus controlling the cell cycle (94). In LSCC, the cell cycle is disrupted owing to a high rate of gene inactivation that regulates CDK4/6 expression, making them potential targets for cancer therapy (95).

CDK4/6 inhibitors have shown promise in treating certain cancers, and their efficacy in treating LSCC is being investigated (96). Regretfully, monotherapy with CDK4/6 inhibitors such as palbociclib and abemaciclib has not been very successful (97, 98). Ongoing research and clinical trials are exploring the potential benefits of CDK4/6 inhibitors, both as monotherapy and in combination with other treatments (99).

2.8 DDR2

Discoidin domain receptor 2 (DDR2) is a member of the RTK family that plays a key role in cell proliferation and survival through EMT (100, 101). Evidence shows that DDR2 signals are closely related to the activation of PI3K/AKT and RAS/MEK/ERK pathways (102). The mutation rate of DDR2 varies among patients with LSCC, ranging from 0 to 4.6%, possibly because of ethnic differences (103–106). A study by Miao et al. demonstrated that DDR2 mRNA levels in LSCC tissue were significantly reduced compared with normal lung tissue (105).

Dasatinib is one of the most effective drugs for inhibiting the proliferation of DDR2-mutated cancer cells and has been approved for leukemia treatment (107). However, its clinical application is limited because of its significant toxicity and complexity of DDR2 signal transduction in lung cancer (102, 108). In addition, the gatekeeper T654I mutation acquired on DDR2 and the deletion of neurofibromin 1 expression through a splice site mutation can result in dasatinib resistance (109). Therefore, it is necessary to fully understand the signal transduction mechanism of DDR2 and develop the second generation of DDR2 inhibitors as soon as possible (110).

3 Other potential treatment targets

In addition to the conventional objectives discussed before, recent novel clinical trials have introduced innovative approaches, generating a treasure trove of valuable data for researchers. The pioneering potential targets might offer a renewed sense of optimism for LSCC treatment. This section delves into a selection of these targets.

3.1 NSD3

The NSD family are selective methyltransferases for histone H3 lysine 36 (H3K36) on nucleosome core particles (111, 112). This family, which operates in an auto-inhibitory state, allows H3K36 dimethylation to be catalyzed by nucleosome-based recognition and modification pathways which is crucial for maintaining chromatin stability and regulating gene expression (113).

Adjacent to FGFR1 is NSD3, which regulates the histone H3 lysine 36 methyltransferase (114). The amplification of NSD3, strongly linked with NSD3 mRNA expression (115), is among the more common genetic alterations in LSCC. Gene set enrichment analysis revealed that MYC targets, E2F targets, G2-M checkpoints, and unfolded protein response (UPR) are highly enriched in NSD3-amplified tumors. Additionally, the non-inflammatory TME condition of NSD3-amplified LSCCs leads to a less-than-optimal clinical response (116). These findings underscore the important carcinogenic function of NSD3 in LSCC and suggest that NSD3 may influence the ability of the immune system to combat tumors.

Considering their substantial role in tumor progression (117), the NSD family is under investigation as a potential therapeutic target for various cancers. However, the development of NSD inhibitors has been slow, largely owing to limitations in bioanalysis methodologies and the unique self-inhibition ring within the SET domain of NSD, making obtaining access to its substrate binding sites challenging (118). Despite these challenges, there has been notable progress in creating small-molecule inhibitors that target specific domains of NSD3 (119, 120), largely attributed to the refinement of the molecular mechanism of histone methylation catalyzed by NSD family proteins. Several inhibitors that target the NSD3 domain or its upstream and downstream signaling targets have been reported, such as BI-9321, a selective antagonist that specifically targets the PWWP1 domain of NSD3, and BRD4, an inhibitor that targets the bromodomain and extraterminal proteins (BET) (120, 121). We look forward to further potential applications of various NSD3 inhibitors.

3.2 KMT2D

The KMT2 family proteins play a pivotal role in chromatin structure regulation through methylation of lysine 3 on histone H4, thereby influencing epigenetic transcriptional activation (75, 122). KMT2D is known for its role as an H3K4 mono-methyltransferase that activates enhancers (123). The KMT2D gene, frequently mutated in LSCC and ranking third in the mutation rate among all cancer-related genes in The Cancer Genome Atlas Pan-Cancer Atlas, is a significant factor in lymphoma and breast cancer (124–127). KMT2D functions as a tumor suppressor in ovarian malignancies and lymphoma; however, it paradoxically promotes tumor growth in gastric and breast cancers (125, 126, 128–130). This dual role highlights the complexity of KMT2D’s function in cancer biology. The role of KMT2D in LSCC remains elusive, but a recent study has shed light on its tumor suppressor function. The study discovered that KMT2D absence leads to the underexpression of receptor-like protein tyrosine phosphatases, resulting in unchecked receptor tyrosine kinases-RAS signaling. The research reveals that inhibiting Src homology-2 protein tyrosine phosphatase and pan-ERBB can mitigate receptor tyrosine kinases-RAS signaling, slow LSCC progression, and extend survival, suggesting that targeting downstream components of KMT2D may be crucial for effective LSCC therapy (131). Furthermore, KMT2D deficiency has been linked to reduced expression of the tumor suppressor gene period circadian regulator 2 in lung cancer, leading to increased glycolysis and tumors proliferating (132).

3.3 KEAP/NRF2

Nuclear factor erythroid 2 related factor 2 (NRF2), a basic leucine zipper (bZIP) transcription factor, is a key regulator related to cell homeostasis (133, 134). Under normal conditions, NRF2 is bound by its repressor, KEAP1, which facilitates the degradation of NRF2 by proteases, maintaining the redox equilibrium (135). The homodimerization of KEAP1 and disruption of the KEAP1-Cullin3 complex under oxidative stress diminishes KEAP1’s ability to target NRF2, allowing NRF2 to enter the nucleus and bind to the regulatory regions of antioxidant genes (136). LUAD frequently exhibits gain-of-function mutations in the NRF2 encoding gene, whereas LSCC is characterized by loss-of-function mutations in KEAP1, affecting ≤21% of cases (137). Furthermore, experimental data indicates that the KEAP1/NRF2 pathway influences cell motility by inhibiting the RAS homolog family member A-Rho-associated protein kinase 1 pathway, affecting tumor cell adhesion and migration (138).

While there is currently no established cure for mutation in this pathway, many innovative and natural electrophilic compounds may serve as potential selective NRF2 activators, exhibiting anti-inflammatory properties (133). This is particularly relevant as NRF2 overactivation in cancer has been linked to chemotherapy and radiation therapy resistance, often resulting in less favorable patient outcomes, such as activating pathways that activate NRF2-mediated cisplatin resistance (137). Additionally, as reported by Sanchez-Ortega et al., reactive oxygen species (ROS) induction in wild-type NRF2/KEAP1 LSCC cells triggers iron death, and local ROS induced generation may be a novel therapeutic strategy for wild-type KEAP1/NRF2 LSCC (139). Surprisingly, Cui et al. found that NRF2 inhibition enhanced cell death and inhibited tumor growth in EGFR-mutated TKI-resistant non-small cell lung cancer, which may provide a new strategy to overcome resistance to EGFR-TKIs (). Furthermore, the physiological mechanism of the KEAP1/NRF2 pathways is intricate, owing to the dual role of NRF2 as both a proto-oncogene and tumor suppressor in cancer (140). There is an urgent need for pharmaceuticals that specifically target the KEAP1/NRF2 signaling pathway and the adoption of advanced therapeutic approaches such as genetic stratification (141). These approaches could potentially provide more effective treatment options for patients.

3.4 USP28

USP28, a member of the deubiquitinase family, plays a crucial role in ubiquitination by removing ubiquitin tags, thereby regulating protein stability and function (142). Studies have highlighted the importance of USP28 in controlling various cancers, including gliomas, bowel cancer, and breast cancer, suggesting its potential as a novel therapeutic target for LSCC (143–145).

F-box and WD repeat domain containing 7 (FBXW7), a crucial component of the ubiquitin ligase complex, targets several well-known oncoproteins for degradation, including c-MYC, neurogenic locus Notch homolog protein, and c-JUN (145). USP28 disrupts this process by preventing FBXW7-mediated ubiquitination (146). Experimental evidence has demonstrated that inhibiting USP28 significantly curtails tumor growth in LSCC. This therapeutic response to USP28 inhibition occurs regardless of FBXW7 and USP28 mutations, underscoring USP28's promise as a therapeutic target in LSCC treatment (147).

Furthermore, studies have delved into the synergistic effects of targeting both USP28 and mevalonate pathways. Abnormalities in the mevalonate pathway are closely linked to tumor growth (148). Within this context, sterol regulatory element-binding protein 2 (SREBP2), a member of the sterol regulatory element-binding proteins, is crucial for cholesterol biosynthesis and uptake (149). Studies have discovered an interaction between SREBP2 and USP28, with both co-localizing in the nucleus of LSCC cells. USP28 can modulate SREBP2 expression, thereby stabilizing it and exerting control over the mevalonate pathway, suppressing tumor growth (150). This insight paves the way for innovative LSCC therapies that target both USP28 and mevalonate pathways, offering promising avenues for treatment.

3.5 p38 MAPK

The p38 MAPK family plays a crucial role in the cellular stress response (151). This kinase group contributes to a stress-response pathway involving three kinase cascades that regulate cell differentiation, survival, and cycle checkpoints (152). Additionally, the dual nature of p38 MAPK has been observed in various cancers, including intestinal, liver, and breast cancer, where it influences both tumor growth and metastasis, making it a potential therapeutic target (153, 154). Despite its promise as a treatment, the clinical application of p38 MAPK inhibitors has been limited owing to systemic adverse effects. Current research is exploring combination therapy and targeting its downstream effectors to enhance its therapeutic efficacy (155). In LSCC context, the role of the p38 pathway in treatment resistance is becoming increasingly clear. Studies have shown that p38 MAPK inhibitors aid in overcoming resistance to gefitinib in NSCLC with EGFR mutations (156). Furthermore, the dual inhibition of FGFR and p38 MAPK has undergone a significant reduction in tumor development and proliferation (157).

3.6 TNFR1

Tumor necrosis factor receptor 1 (TNFR1) is a key mediator of the physiological effects of TNF (158). It activates the nuclear factor-κB (NF-κB) and MAPK pathway, causing necrotic apoptosis (159). The NF-κB pathway, connected to TNFR1, is an important molecular mechanism involved in various cellular processes such as innate immunity, inflammation, cell development, survival, and proliferation (160, 161).

TNFR1, through the NF-κB signaling pathway, stimulates the production of ubiquitin-conjugating Enzyme H10 (UBCH10), an E2 ubiquitin-conjugating enzyme. Activated UBCH10 reduces twist-related protein 1, c-MYC, and SRY-box transcription factor 2 (SOX2) levels, leading to the transformation of differentiated LSCC into dedifferentiated spindle cell carcinoma, contributing to the last stage of LSCC (162). The TNFR1–UBCH10 axis plays a crucial role in LSCC development and metastasis, positioning TNFR1 inhibitors as potential novel treatments for LSCC (Table 1).

Table 1

DrugsTargetDrug typeCancer type
Piqray (alpelisib)PI3KSmall molecular inhibitorBreast cancer
Ukoniq (umbralisib)PI3KSmall molecular inhibitorLymphoma
GedatolisibPI3K/mTORSmall molecular inhibitorColorectal cancer
Truqap (capivasertib) with fulvestrantHR-positive and HER2-negative with PIK3CA/AKT1/PTEN-alterationsSmall molecular inhibitorBreast cancer
Anti-EGFR/VEGFR2 BsAbEGFR and VEGFR2AntibodyTriple-negative breast cancer
Erbitux (cetuximab)EGFR and KRASAntibodyColorectal cancer or squamous cell carcinoma of the head and neck
FutibatinibFGFRSmall molecular inhibitorHead and neck cancer
CYY292FGFR1Small molecular inhibitorLocally advanced and metastatic cancer
SulfatinibFGFR1Small molecular inhibitorOsteosarcoma
NaporafenibRASSmall molecular inhibitorMelanoma
PLX8394RAFSmall molecular inhibitorSolid tumor
NFX-179MEKSmall molecular inhibitorCutaneous squamous cell carcinoma
Tepmetko (tepotinib)METSmall molecular inhibitorNon-small-cell lung cancer
PalbociclibCDK4/6 and STAT3Small molecular inhibitorBreast cancer
ThapsigarginNSD3 (UPR)Small molecular inhibitorLung squamous cell carcinoma
SHP099KMT2DSmall molecular inhibitorLung squamous cell carcinoma
ML385NRF2 and AKTSmall molecular inhibitorLung squamous cell carcinoma
Otilonium bromideUSP28Small molecular inhibitorColorectal cancer
Vismodegib derivativesUSP28Small molecular inhibitorColorectal cancer and lung squamous cell carcinoma
Resveratrol (RES)HMMR (CD168)PolyphenolLung squamous cell carcinoma
FelodipineNFAT1Small molecular inhibitorLung squamous cell carcinoma

Existing drugs that might be used in targeting LSCC.

4 Targeted therapy combined with immunotherapy

At present, immunotherapy stands as an important treatment option for patients with LSCC. Each of these treatments, immunotherapy, chemotherapy, and targeted therapy, faces challenges owing to the diversity of tumor phenotypes and suboptimal clinical response when used independently. Therefore, exploring the potential for combined targeted therapy and immunotherapy could significantly improve patient outcomes.

4.1 Classical pathway with immunotherapy

TMB is a crucial parameter for assessing immunotherapy effectiveness (163). Patients with a high TMB are more likely to benefit from ICI medications (164). High TMB (≥10/Mb) tumors in LSCC demonstrate enhanced immune cell lysis activity and enrichment of CD8+ T cells compared with low TMB cancers. Furthermore, research indicates that seven pathways, including the traditional PI3K/AKT and MAPK, are significantly inversely associated with TMB in LSCC (165).

Recent research suggests that PI3K inhibitors exert specific effects on TME by regulating tumor vasculature, fibroblast activity, and associated protein secretion (166). PI3K-δ and PI3K-γ signaling pathways alter the intrinsic processes of cell populations and influence tumor immune microenvironment (TIME), thereby supporting T-cell inhibition (167). Furthermore, alterations in the PI3K pathway in head and neck squamous cell carcinoma (HNSCC) have been associated with a high density of cytotoxic cells, including central memory CD8+ T and memory CD4+ T cells, which are crucial for immunotherapy and anti-tumor immunity (168).

KRAS mutations, prevalent in NSCLC, have been associated with increased PD-L1 expression, proliferation of tumor-infiltrating lymphocytes (TILs) proliferation, and high TMB (84, 169). Clinical trials suggest that ICIs are effective for patients with specific KRAS mutations, especially the G12C subtype (170). However, not all KRAS mutations are equally responsive to immunotherapy. For instance, the G12D variant is linked to lower TMB and, when co-mutated with TP53, shows reduced PD-L1 expression and immune infiltration (171). Given the prevalence of the G12C subtype in KRAS mutations and the FDA-approval of targeted drugs for this subtype, the synergistic approach of immunotherapy and KRAS targeted therapy holds considerable promise (83).

Additionally, the cell cycle pathway shows a significant positive correlation with TMB in both LUAD and LSCC. Inhibition of CDK4/6 is known to enhance T cell activation, bolster tumor immunological infiltration, reinforce immunological memory, and amplify the anti-tumor immunity elicited by anti-PD-1 antibodies (172, 173). Evidence from ovarian cancer treatment indicates that the synergistic effects of anti-PD-1 and CDK4/6 targeted therapy surpass the benefits of either treatment alone (174). Innovative combinations, such as the CDK4/6 inhibitor palbociclib and the CD73 selective inhibitor AB680, have shown efficacy in colorectal cancer (175). These findings provide hope for the potential of these combinations to increase their efficacy.

4.2 KEAP/NRF2 with immunotherapy

The mutation of the KEAP/NRF2 pathway is associated with a poor prognosis in patients with advanced cancer (176). In addition to being a significant targeted therapeutic option, this pathway mutation influences TIME and the selection of immunotherapy for patients with NSCLC (177). Recent clinical research has highlighted certain tumor metabolic characteristics, such as NRF2-mediated glutamine metabolism, that regulate tumor TIME (178). Glutamate and glutamine metabolism is significantly upregulated in LSCC tissues and plays a significant role in immune and stromal environmental inhibition (179). Immunotherapy for lung cancer benefits from inhibiting the glutamine metabolic pathway in several manners, including the upregulation of PD-L1 expression and reactivation of CD8+ T cells (177, 180). Furthermore, elevated NRF2 levels induce cell senescence. These senescent cells can be eliminated by immune effector cells recruited by NRF2-induced secretory phenotype, establishing the NRF2- NRF2-induced secretory phenotype immune surveillance axis (176).

Considering the multifaceted roles of the KEAP1/NRF2 pathway in both immunotherapy and targeted therapy, combining these two approaches may enhance clinical outcomes for patients with LSCC.

4.3 NSD3 with immunotherapy

Considering the significant variability of tumor immunogenicity and clinical response in patients with LSCC, precise stratification of immunotherapies is crucial. The TME of NSD3-amplified LSCC exhibits a non-inflammatory state with diminished activity in immune-related pathways. High UPR signaling activity may be a major modulator of the non-inflammatory TME phenotype in NSD3-amplified LSCC, as suggested by further molecular characterization (116). This suggests that NSD3 influences TIME and is linked to poorer outcomes in LSCC immunotherapy. Furthermore, NSD3 mutations impact clinical outcomes as they are related to immune cell infiltration and growth signaling in pancreatic cancer (112). While there are currently no therapeutically available NSD3 inhibitors, NSD3 could potentially serve as a biomarker for immunotherapy in combination with targeted therapy.

4.4 KMT2D with immunotherapy

Evidence suggests that patients with mutant KMT2D are likely to respond favorably to immunotherapy, as indicated by the protein's high attachment to major histocompatibility class I (181). Tumors with KMT2D mutations have been observed to exhibit a significantly higher TMB and improved immune infiltration in TIME (125, 182, 183). Furthermore, KMT2D mutations have been found to enhance immunotherapy responses in certain cancers (184). DNA damage, increased mutation burden, intron retention, and activated TE expression contribute to elevated neoantigen synthesis (185). Additionally, KMT2D has been linked to mismatch repair deficiency in prostate cancer (186). KMT2D mutations have been identified as potential predictive markers for melanoma and effective predictors of immune response in colorectal cancer (187, 188). The combination of immunotherapy and targeted therapy for KMT2D holds promising potential for improving treatment outcomes.

4.5 P38 MAPK with immunotherapy

Research indicates that 3-hydroxy-3-methylglutaryl-CoA reductase, an essential enzyme in the mevalonate pathway, regulates the production of PD-1 via p38 MAPK (189). Observations suggest that inhibiting the p38 MAPK pathway stimulates CD8+/CD4+ T cells and fosters the growth of CD8+ T cells (190, 191). A potential treatment approach could involve a temporary boost in immunity by co-blocking PD-1 and p38 MAPK (191). However, p38 MAPK activation in CD8+ T cells compromises the anti-tumor efficacy of some anti-PD-L1 therapies, indicating that a combination of anti-PD-L1 and p38 MAPK-targeted therapies may hold potential (192). Furthermore, a combination of anti-PD-1 therapy and metformin, a drug known to boost the anticancer activity of natural killer cells in a p38 MAPK-dependent manner, may be effective against metastatic melanoma (193).

4.6 TNFR1 with immunotherapy

TNFR1 is crucial for anti-tumor immunity, potentially predicting the immune response (194). In addition, TNFR1 is required for the TNF signaling pathway in melanoma, affecting the efficacy of anti-PD-1 therapy. After anti-PD-1 therapy, TNF insufficiency reduces TIL mortality and increases CD8+ TIL numbers, with similar effects observed in lung cancer (195). Studies suggest that TNFR1 modulates immune cell expression and enhances anti-tumor activity through NF-κB and p38 MAPK signaling cascade, regulating anti-tumor immunity, which is crucial for NSCLC development (196, 197). Furthermore, TNFR1 and interferon-γ signaling cooperate to prevent multistage carcinogenesis as a compromise in either pathway may cause T lymphocytes to promote tumor formation (198).

5 Multi-target combination therapy

5.1 FGFR1 and MAPK

Although several FGFR1 inhibitors have been tested, their clinical effectiveness is limited owing to resistance in various cancers, including lung, breast, colorectal, and melanoma (199, 200). A clinical study suggests that the TAM family of tyrosine kinases, MET, neurotrophic factor receptor pathway, and MAPK pathway are major contributors to FGFR resistance. Specific genes such as KRAS G13D, HRAS, MAP3K8, and BRAF V600E within the MAPK pathway are linked to resistance against the FGFR inhibitor BGJ398 (201). The latter three gene mutations are responsible for PI3K inhibition in breast cancer and RAF/MEK inhibition in BRAF-mutated melanoma (202, 203). BGJ398 inhibits FGFR by deactivating AKT phosphorylation and temporarily suppressing ERK phosphorylation in the NCI-H2077 cell line. However, overexpression of neurotrophic factor receptor pathway 1, MET, and HRAS leads to the resurgence of ERK and AKT activity, indicating an up-regulation trend in ERK activity (201). Increased MAPK signaling gene expression signaling and p38 phosphorylation are common in FGFR inhibitor-sensitive cell lines. Moreover, p38 MAPK overexpression can diminish the effectiveness of FGFR inhibition, inducing resistance (157).

Specifically, in lung cancer cell lines with amplified FGFR1, MET overexpression induces resistance to FGFR inhibitors, indicating a possible inverse correlation between these pathways (204).

5.2 FGFR and EGFR

Commonly used EGFR-TKIs in clinical practice include gefitinib, erlotinib, and afatinib. However, drug resistance remains a challenge (205). KRAS G13D and BRAF V600E, two MAPK family members, increase resistance to erlotinib, gefitinib, and crizotinib in NSCLC and contribute to resistance against FGFR inhibitors (201). Activation of the FGF2/FGFR1 autocrine pathway in EGFR-dependent NSCLC leads to resistance to gefitinib and osimertinib, indicating a potential connection between the FGFR and EGFR pathways (206, 207). In lung cancer cell lines with the FGF2/FGFR1 pathway, targeting this resistance mechanism with EGFR-specific TKI does not significantly increase apoptosis, indicating that FGFR inhibitors may stabilize tumor progression rather than cause tumor regression (208). Therefore, combining FGFR-specific TKIs with EGFR-specific TKIs may serve as an effective targeted therapy for LSCC, potentially delaying the development of acquired resistance in EGFR-driven NSCLC.

5.3 PI3K and KMT2D

Studies have demonstrated that KMT2D modulates SOX2 expression in NSCLC through a PI3K-dependent manner, significantly impacting tumor growth. A KMT2D deficiency leads to reduced phosphoinositide-3-kinase-interacting protein 1 expression and increased phosphorylated AKT, accelerating tumor growth in NSCLC by activating the PI3K/AKT pathway and upregulating SOX2 expression (209). Inhibiting PI3K affects tumor growth in estrogen receptor (ER)-positive breast cancer and activates glucocorticoid-regulated kinase 1 through KMT2D, regulating ER-dependent transcription via a negative feedback loop (126, 210). Patients with ER-positive breast cancer may gain clinical benefit from the combined targeted therapy of KMT2D and PI3K, potentially increasing efficacy and preventing resistance to PI3K inhibition (211, 212). Although promising, these results are preliminary and more research is required to determine the effectiveness of KMT2D and PI3K targeted therapy in LSCC treatment. Considering KMT2D’s role in the PI3K/AKT/SOX2 axis in NSCLC, which affects tumor growth, combined targeted therapy of KMT2D and PI3K may offer new treatment possibilities for LSCC.

6 Discussion

This review explores the current landscape of targeted therapy for LSCC, highlighting both established and emerging targets. Targeted therapies have proven beneficial in LUAD treatment (213, 214). Patients with LSCC exhibit distinct genetic alterations from LUAD; thus, their therapeutic options remain limited (215). The scarcity of therapeutic targets, coupled with modest efficacy and prevalent adverse effects, underscores the need to expand or discover new targets. The NSD family, especially NSD3, is strongly linked to the development of several malignant cancers. The pathogenic mechanism and structure of NSD3 have been largely established. The link between LSCC pathogenesis and KMT2D deficiency has been established, paving the way for the increased development of targeted drugs. NSD3 and KMT2D are promising therapeutic targets, offering hope for the enhancement of treatment strategies for LSCC. The advent of immunotherapy has significantly improved the treatment of patients with LSCC. Nonetheless, limitations such as low immune response rates and drug resistance persist. This study delves into the potential advantages of integrating immunotherapy with targeted therapy and benefits of multi-target combination therapy are discussed.

It is vital to identify appropriate biomarkers to optimize the clinical effectiveness of targeted therapies. KEAP1 has been identified as one of the significantly mutated genes in LSCC (51). In a Japanese retrospective cohort study, approximately 13.4% of patients with LSCC carried the KEAP1 mutation (216). Blocking glutamine metabolism targeting the KEAP/NRF2 pathway is a promising therapeutic strategy. The broad-acting glutamine antagonist sirpiglenastat has been shown to induce anti-tumor efficacy (217), and has therapeutic potential in HNSCC (218). In a recent Lung-MAP next-generation sequencing analysis, David Kozono’s team found that NFE2L2, KEAP1 and PARP4 are a mutually exclusive set of gene mutations (219), indicating KEAP1 as a potential biomarker in LSCC. In addition, recent research suggests that two members of the sequence similarity family, FAM20A and FAM83A, have potential clinical applications in lung squamous cell carcinoma. A recent study based on genomic databases and analysis of clinical samples showed that FAM20A was significantly reduced in LSCC and positively correlated with immune checkpoints such as CTLA-4, leading to reduced survival (220). Moreover, Lu et al. found that FAM83A, which is overexpressed in LSCC, can promote LSCC cell growth by activating the Wnt/β-catenin signaling pathway, and is a potential biomarker (221).

Epigenetic targeted drugs have promise in treating hematological malignancies and solid tumors, with tazemetostat potentially improving outcomes in solid tumors (222, 223). Furthermore, the epigenetic landscape of LSCC has become clear; for example, the demethylation of cancer/testicular antigen is highly associated with lung cancer, with its expression correlating with the immune microenvironment of NSCLC, offering diagnostic and prognostic insights (224, 225). Promoter hypermethylation promotes the transcriptional silencing of tumor suppressor genes, facilitating LSCC diagnosis and prognosis prediction. Studies have proposed various molecular drugs targeting the epigenetic network of LSCC to revert cancer cells to normalcy, including repaglinide, procainamide, and clomipramine (226). DNA methyltransferases, histone methyltransferase enhancer of zeste homolog 2, and so on are potential targets for targeted therapies, indirectly increasing targeted therapies’ efficacy (227). Additionally, NSD3 and KMT2D, as potential new targets, are vital substances in epigenetic regulation, linking targeted and epigenetic therapy. Their roles in histone methyl transfer may pave the way for LSCC innovative treatment through the synergy of epigenetics and targeted therapies. Epigenetic therapy can reverse the resistance mechanisms of gene changes and transcriptional reprogramming (228–231). The potential of combined targeted therapy of DNA methyltransferase inhibitors and venetoclax (antiapoptotic B-cell lymphoma 2 protein inhibitor) in treating hematological malignancies was investigated, and this combination therapy was recognized as a “breakthrough therapy” by the FDA for patients with specific acute myeloid leukemia (228, 232–234). Therefore, epigenetic therapy can also complement targeted therapies by combining, significantly improving efficacy.

Furthermore, emerging antibody-drug conjugates (ADCs) offer a fresh perspective. ADCs comprise a monoclonal antibody that selectively targets specific tumor cell proteins and is linked to a cytotoxic drug known as the payload (235). As of August 2023, fifteen ADCs have been globally approved, targeting molecules such as human epidermal growth factor receptor 2, trophoblast antigen 2, nectin-4, CD22, and CD33. Among these, the ADC cetuximab saratolacan, targeting EGFR, has been approved for HNSCC (236). Early trials in NSCLC suggest potential benefits from ADCs such as trastuzumab emtansine, patritumab deruxtecan, and sacituzumab govitecan (237–239). Moreover, the bispecific delta-like canonical Notch ligand 3/CD3 IgG-like T-cell engager, which binds to both delta-like canonical Notch ligand 3 and immune cells, has inspired therapeutic drugs and antibodies to enhance treatment efficacy (240). The potential of combining targeted therapeutic drugs with antibodies to form conjugates akin to the ADCs is an area of interest for researchers. Furthermore, EGFR inhibition enhances the therapeutic effect of ADC HER3-DXd, suggesting the potential of combining targeted therapy with ADCs for more effective treatment (241).

Considering the landscape of targeted therapy for LSCC, we recommend the following clinical patient selection strategies. Age, smoking status, and overall health can inform eligibility for specific treatment options. Using genomic tests to detect mutated genes and immunohistochemical tests to detect PD-L1 levels facilitates the identification of potential therapeutic targets and development of combination treatment strategies. Finally, with patient knowledge and committee approval, patients may be encouraged to participate in clinically targeted drug trials to improve treatment effectiveness. The integration of various therapeutic options, and updating of clinical practice and research are of great significance to the improvement of therapeutic benefits.

Statements

Author contributions

WC: Writing – review & editing. QC: Writing – original draft. XZ: Writing – original draft. JL: Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Glossary

  • ADCs

    Antibody-drug conjugates

  • AKT

    Protein kinase B

  • ALK

    Anaplastic lymphoma kinase

  • BRAF

    V-raf murine sarcoma viral oncogene homolog B

  • CDK4/6

    Cell cycle protein-dependent kinases 4 and 6

  • DDR2

    Discoidin domain receptor 2

  • EGFR

    Epidermal growth factor receptor

  • ER

    Estrogen receptor

  • FGFR

    Fibroblast growth factor receptor

  • ICIs

    Immune checkpoint inhibitors

  • KEAP1

    Kelch-like ECH-associated protein 1

  • KMT2D

    Lysine methyltransferase 2 D

  • KRAS

    Kirsten rat sarcoma virus

  • LSCC

    Lung squamous cell carcinoma

  • LUAD

    Lung adenocarcinoma

  • MEK

    Mitogen-activated protein kinase kinase

  • NF-κB

    Nuclear factor-κB

  • NRF2

    Nuclear factor erythroid 2 related factor 2

  • NSCLC

    Non-small cell lung cancer

  • NSD3

    Nuclear receptor-binding SET domain protein 3

  • P38 MAPK

    P38 mitogen-activated protein kinases

  • PD-L1

    Programmed Cell Death Ligand 1

  • PD-1

    Programmed Cell Death Protein 1

  • PI3K

    Phosphoinositide 3-kinase

  • RAS

    Rat sarcoma

  • SOX2

    SRY-box transcription factor 2

  • TILs

    Tumor-infiltrating lymphocytes

  • TIME

    Tumor immune microenvironment

  • TKI

    Tyrosine kinase inhibitor

  • TMB

    Tumor mutational burden

  • TME

    Tumor microenvironment

  • TNFR1

    Tumor necrosis factor receptor 1

References

  • 1

    TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalA. Global cancer statistics, 2012. CA Cancer J Clin. (2015) 65:87–108. doi: 10.3322/caac.21262

  • 2

    LiangCPanWZhouZLiuX. Identification of prognostic biomarkers of smoking-related lung cancer. J Thorac Dis. (2024) 16:1438–49. doi: 10.21037/JTD-23-1890/COIF

  • 3

    HeistRSSequistLVEngelmanJA. Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol. (2012) 7:924–33. doi: 10.1097/JTO.0b013e31824cc334

  • 4

    ZhangQCaiGCuiFLiFLiangHGaoLet al. The relationship of airflow limitation with lung squamous cell carcinoma: evidence from mendelian randomization analysis. J Cancer Res Clin Oncol. (2023) 149:6999–7006. doi: 10.1007/s00432-023-04612-6

  • 5

    KhuderSAMutgiAB. Effect of smoking cessation on major histologic types of lung cancer. Chest. (2001) 120:1577–83. doi: 10.1378/chest.120.5.1577

  • 6

    ChengYZhangTXuQ. Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm (Beijing). (2021) 2:692–729. doi: 10.1002/MCO2.105

  • 7

    JeongYHoangNTLovejoyAStehrHNewmanAMGentlesAJet al. Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance. Cancer Discovery. (2017) 7:86–101. doi: 10.1158/2159-8290.CD-16-0127

  • 8

    KimYHammermanPSKimJYoonJALeeYSunJMet al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. (2014) 32:121–8. doi: 10.1200/JCO.2013.50.8556

  • 9

    PanYHanHLabbeKEZhangHWongK-K. Recent advances in preclinical models for lung squamous cell carcinoma. Oncogene. (2021) 40:2817–29. doi: 10.1038/s41388-021-01723-7

  • 10

    XiaW-YFengWZhangC-CShenY-JZhangQYuWet al. Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review. Transl Lung Cancer Res. (2020) 9:2120–36. doi: 10.21037/tlcr-20-827

  • 11

    GuoQLiuLChenZFanYZhouYYuanZet al. Current treatments for non-small cell lung cancer. Front Oncol. (2022) 12:945102. doi: 10.3389/fonc.2022.945102

  • 12

    KimES. Chemotherapy resistance in lung cancer. Adv Exp Med Biol. (2016) 893:189–209. doi: 10.1007/978-3-319-24223-1_10

  • 13

    VojtíšekR. Cardiac toxicity of lung cancer radiotherapy. Rep Pract Oncol Radiother. (2020) 25:13–9. doi: 10.1016/j.rpor.2019.10.007

  • 14

    AlbertiWAndersonGBartolucciABellDVillalbaJBBrodinOet al. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. (1995) 311:899–909.

  • 15

    KanZJaiswalBSStinsonJJanakiramanVBhattDSternHMet al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. (2010) 466:869–73. doi: 10.1038/nature09208

  • 16

    BrahmerJRTykodiSSChowLQMHwuW-JTopalianSLHwuPet al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. (2012) 366:2455–65. doi: 10.1056/NEJMoa1200694

  • 17

    TopalianSLHodiFSBrahmerJRGettingerSNSmithDCMcDermottDFet al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. (2012) 366:2443–54. doi: 10.1056/NEJMoa1200690

  • 18

    PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. (2012) 12:252–64. doi: 10.1038/nrc3239

  • 19

    van den BulkJVerdegaalEMde MirandaNF. Cancer immunotherapy: broadening the scope of targetable tumours. Open Biol. (2018) 8. doi: 10.1098/rsob.180037

  • 20

    TumehPCHarviewCLYearleyJHShintakuIPTaylorEJMRobertLet al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. (2014) 515:568–71. doi: 10.1038/nature13954

  • 21

    PennockGKChowLQM. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. (2015) 20:812–22. doi: 10.1634/theoncologist.2014-0422

  • 22

    YuanHLiuJZhangJ. The current landscape of immune checkpoint blockade in metastatic lung squamous cell carcinoma. Molecules. (2021) 26. doi: 10.3390/molecules26051392

  • 23

    SharmaPAllisonJP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. (2015) 161:205–14. doi: 10.1016/j.cell.2015.03.030

  • 24

    AldeaMAndreFMarabelleADoganSBarlesiFSoriaJ-C. Overcoming resistance to tumor-targeted and immune-targeted therapies. Cancer Discovery. (2021) 11:874–99. doi: 10.1158/2159-8290.CD-20-1638

  • 25

    YangMLinCWangYChenKZhangHLiW. Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance. Genome Med. (2022) 14. doi: 10.1186/S13073-022-01079-X

  • 26

    ShuklaSARooneyMSRajasagiMTiaoGDixonPMLawrenceMSet al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. (2015) 33:1152–8. doi: 10.1038/NBT.3344

  • 27

    LiuLUXieBZhuWHeQZhouJLiuSet al. High expression of PD-L1 mainly occurs in non-small cell lung cancer patients with squamous cell carcinoma or poor differentiation. Oncol Res. (2023) 31:275–86. doi: 10.32604/or.2023.028227

  • 28

    Kamel-ReidSChongGIonescuDNMaglioccoAMSpatzATsaoMet al. EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer. Curr Oncol. (2012) 19:e67–74. doi: 10.3747/co.19.862

  • 29

    ChoiJ-SKangH-MNaKKimJKimT-WJungJet al. KEAP1-NRF2 pathway as a novel therapeutic target for EGFR-mutant non-small cell lung cancer. Tuberc Respir Dis (Seoul). (2024). doi: 10.4046/TRD.2024.0087

  • 30

    ZhouSWangHJiangWYuQ. Clinicopathological characteristics and EGFR-TKIs efficacies in lung squamous cell carcinoma patients harboring an EGFR sensitizing mutation. Onco Targets Ther. (2019) 12:8863–71. doi: 10.2147/OTT.S225760

  • 31

    ArafehRSamuelsY. PIK3CA in cancer: The past 30 years. Semin Cancer Biol. (2019) 59:36–49. doi: 10.1016/j.semcancer.2019.02.002

  • 32

    Sanchez-VegaFMinaMArmeniaJChatilaWKLunaALaKCet al. Oncogenic signaling pathways in the cancer genome atlas. Cell. (2018) 173:321–337.e10. doi: 10.1016/j.cell.2018.03.035

  • 33

    VanhaesebroeckBGuillermet-GuibertJGrauperaMBilangesB. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. (2010) 11:329–41. doi: 10.1038/nrm2882

  • 34

    JankuF. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. Cancer Treat Rev. (2017) 59:93–101. doi: 10.1016/j.ctrv.2017.07.005

  • 35

    PengYWangYZhouCMeiWZengC. PI3K/akt/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol. (2022) 12:819128. doi: 10.3389/FONC.2022.819128

  • 36

    MadsenRRVanhaesebroeckBSempleRK. Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol Med. (2018) 24:856–70. doi: 10.1016/j.molmed.2018.08.003

  • 37

    LauSCMPanYVelchetiVWongKK. Squamous cell lung cancer: Current landscape and future therapeutic options. Cancer Cell. (2022) 40:1279–93. doi: 10.1016/j.ccell.2022.09.018

  • 38

    Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. (2012) 489:519–25. doi: 10.1038/nature11404

  • 39

    MukherjeeRVanajaKGBoyerJAGadalSSolomonHChandarlapatySet al. Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis. Mol Cell. (2021) 81:708–723.e5. doi: 10.1016/j.molcel.2021.01.033

  • 40

    CavazzoniALa MonicaSAlfieriRRavelliAvan der SteenNSciarrilloRet al. Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. Oncotarget. (2017) 8:53068–83. doi: 10.18632/oncotarget.18087

  • 41

    HuangQZhouYWangBZhaoYZhangFDingB. Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population. BMC Med Genomics. (2022) 15:146. doi: 10.1186/s12920-022-01297-7

  • 42

    LiaoRGWatanabeHMeyersonMHammermanPS. Targeted therapy for squamous cell lung cancer. Lung Cancer Manag. (2012) 1:293–300. doi: 10.2217/lmt.12.40

  • 43

    FrumanDARommelC. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discovery. (2014) 13:140–56. doi: 10.1038/nrd4204

  • 44

    YapTAYanLPatnaikAFearenIOlmosDPapadopoulosKet al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. (2011) 29:4688–95. doi: 10.1200/JCO.2011.35.5263

  • 45

    ArteagaCL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol. (2002) 29:3–9. doi: 10.1053/sonc.2002.35642

  • 46

    KosakaTYatabeYEndohHKuwanoHTakahashiTMitsudomiT. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. (2004) 64:8919–23. doi: 10.1158/0008-5472.CAN-04-2818

  • 47

    ShigematsuHLinLTakahashiTNomuraMSuzukiMWistubaIIet al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. (2005) 97:339–46. doi: 10.1093/jnci/dji055

  • 48

    TanACTanDSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. (2022) 40:611–25. doi: 10.1200/JCO.21.01626

  • 49

    Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy - PubMed . Available online at (Accessed September 17, 2024).

  • 50

    SatpathySKrugKJean BeltranPMSavageSRPetraliaFKumar-SinhaCet al. A proteogenomic portrait of lung squamous cell carcinoma. Cell. (2021) 184:4348–4371.e40. doi: 10.1016/J.CELL.2021.07.016

  • 51

    NiuZJinRZhangYLiH. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Signal Transduct Target Ther. (2022) 7. doi: 10.1038/S41392-022-01200-X

  • 52

    YeZHuangYKeJZhuXLengSLuoH. Breakthrough in targeted therapy for non-small cell lung cancer. BioMed Pharmacother. (2021) 133. doi: 10.1016/J.BIOPHA.2020.111079

  • 53

    ChenZVallegaKAWangDQuanZFanSWangQet al. Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer. J Exp Med. (2024) 221. doi: 10.1084/JEM.20240435

  • 54

    WangZZhouFXuSWangKDingH. The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis. Cancer Med. (2023) 12:18516–30. doi: 10.1002/cam4.6453

  • 55

    DaiSZhouZChenZXuGChenY. Fibroblast growth factor receptors (FGFRs): structures and small molecule inhibitors. Cells. (2019) 8. doi: 10.3390/cells8060614

  • 56

    TurnerNGroseR. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. (2010) 10:116–29. doi: 10.1038/nrc2780

  • 57

    WeissJSosMLSeidelDPeiferMZanderTHeuckmannJMet al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. (2010) 2:62ra93. doi: 10.1126/scitranslmed.3001451

  • 58

    GroseRDicksonC. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. (2005) 16:179–86. doi: 10.1016/J.CYTOGFR.2005.01.003

  • 59

    McKeehanWLWangFKanM. The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol. (1998) 59:135–76. doi: 10.1016/S0079-6603(08)61031-4

  • 60

    TiongKHTanBSChooHLChungFFLHiiLWTanSHet al. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival. Oncotarget. (2016) 7:57633–50. doi: 10.18632/ONCOTARGET.9328

  • 61

    FengSDakhovaOCreightonCJIttmannM. Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. Cancer Res. (2013) 73:2551–62. doi: 10.1158/0008-5472.CAN-12-4108

  • 62

    ZhaoXXuFDominguezNPXiongYXiongZPengHet al. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression. Mol Carcinog. (2018) 57:1616–25. doi: 10.1002/MC.22884

  • 63

    LiFLiZHanQChengYJiWYangYet al. Enhanced autocrine FGF19/FGFR4 signaling drives the progression of lung squamous cell carcinoma, which responds to mTOR inhibitor AZD2104. Oncogene. (2020) 39:3507–21. doi: 10.1038/S41388-020-1227-2

  • 64

    Nagao-KitamotoHNagataMNaganoSKitamotoSIshidouYYamamotoTet al. GLI2 is a novel therapeutic target for metastasis of osteosarcoma. Int J Cancer. (2015) 136:1276–84. doi: 10.1002/IJC.29107

  • 65

    ZhangYWuTWangYChenZChenJLuSet al. Reciprocal FGF19-GLI2 signaling induces epithelial-to-mesenchymal transition to promote lung squamous cell carcinoma metastasis. Cell Oncol (Dordr). (2023) 46:437–50. doi: 10.1007/S13402-022-00760-Y

  • 66

    KatohM. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat Rev Clin Oncol. (2019) 16:105–22. doi: 10.1038/s41571-018-0115-y

  • 67

    CarterEPFearonAEGroseRP. Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends Cell Biol. (2015) 25:221–33. doi: 10.1016/j.tcb.2014.11.003

  • 68

    HongSHKimTM. High-resolution genomic configuration of FGFR rearrangements dictates the therapeutic vulnerability of squamous cell lung cancers. Transl Lung Cancer Res. (2024) 13:236–9. doi: 10.21037/TLCR-23-705/COIF

  • 69

    BilslandJGWheeldonAMeadAZnamenskiyPAlmondSWatersKAet al. Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications. Neuropsychopharmacology. (2008) 33:685–700. doi: 10.1038/SJ.NPP.1301446

  • 70

    GoldingBLuuAJonesRViloria-PetitAM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. (2018) 17:1–15. doi: 10.1186/S12943-018-0810-4

  • 71

    SodaMChoiYLEnomotoMTakadaSYamashitaYIshikawaSet al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. (2007) 448:561–6. doi: 10.1038/NATURE05945

  • 72

    OuSHIZhuVWNagasakaM. Catalog of 5’ Fusion partners in ALK-positive NSCLC circa 2020. JTO Clin Res Rep. (2020) 1. doi: 10.1016/J.JTOCRR.2020.100015

  • 73

    ChiaPLDobrovicADobrovicAJohnT. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol. (2014) 6:423–32. doi: 10.2147/CLEP.S69718

  • 74

    ShawATYeapBYMino-KenudsonMDigumarthySRCostaDBHeistRSet al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. (2009) 27:4247–53. doi: 10.1200/JCO.2009.22.6993

  • 75

    TinsleyEBredinPToomeySHennessyBTFurneySJ. KMT2C and KMT2D aberrations in breast cancer. Trends Cancer. (2024) 10:519–30. doi: 10.1016/J.TRECAN.2024.02.003

  • 76

    WuJSavoojiJLiuD. Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol. (2016) 9:1–7. doi: 10.1186/S13045-016-0251-8

  • 77

    TestaUCastelliGPelosiE. Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting. Tumori. (2024) 110:88–95. doi: 10.1177/03008916231202149

  • 78

    PengLZhuLSunYStebbingJSelvaggiGZhangYet al. Targeting ALK rearrangements in NSCLC: current state of the art. Front Oncol. (2022) 12:863461. doi: 10.3389/FONC.2022.863461

  • 79

    LiuFYangXGengMHuangM. Targeting ERK, an Achilles’ Heel of the MAPK pathway, in cancer therapy. Acta Pharm Sin B. (2018) 8:552–62. doi: 10.1016/J.APSB.2018.01.008

  • 80

    VetterIRWittinghoferA. The guanine nucleotide-binding switch in three dimensions. Science. (2001) 294:1299–304. doi: 10.1126/SCIENCE.1062023

  • 81

    McCubreyJASteelmanLSChappellWHAbramsSLWongEWTChangFet al. Roles of the Raf/MEK/ERK pathway in cell growth, Malignant transformation and drug resistance. Biochim Biophys Acta. (2007) 1773:1263–84. doi: 10.1016/J.BBAMCR.2006.10.001

  • 82

    HassanBAkcakanatAHolderAMMeric-BernstamF. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am. (2013) 22:641–64. doi: 10.1016/J.SOC.2013.06.008

  • 83

    MooreARRosenbergSCMcCormickFMalekS. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discovery. (2020) 19:533–52. doi: 10.1038/S41573-020-0068-6

  • 84

    DeardenSStevensJWuYLBlowersD. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. (2013) 24:2371–6. doi: 10.1093/ANNONC/MDT205

  • 85

    AckerFStratmannJAspacherLNguyenNTTWagnerSServeHet al. KRAS mutations in squamous cell carcinomas of the lung. Front Oncol. (2021) 11:788084. doi: 10.3389/FONC.2021.788084

  • 86

    ShaulYDSegerR. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. (2007) 1773:1213–26. doi: 10.1016/J.BBAMCR.2006.10.005

  • 87

    DegirmenciUWangMHuJ. Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells. (2020) 9. doi: 10.3390/CELLS9010198

  • 88

    YaegerRCorcoranRB. Targeting alterations in the RAF-MEK pathway. Cancer Discovery. (2019) 9:329–41. doi: 10.1158/2159-8290.CD-18-1321

  • 89

    HauraEBRicartADLarsonTGStellaPJBazhenovaLMillerVAet al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res. (2010) 16:2450–7. doi: 10.1158/1078-0432.CCR-09-1920

  • 90

    BlumenscheinGRSmitEFPlanchardDKimDWCadranelJDe PasTet al. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. Ann Oncol. (2015) 26:894–901. doi: 10.1093/ANNONC/MDV072

  • 91

    HanJLiuYYangSWuXLiHWangQ. MEK inhibitors for the treatment of non-small cell lung cancer. J Hematol Oncol. (2021) 14:1–12. doi: 10.1186/S13045-020-01025-7

  • 92

    HumeSDianovGLRamadanK. A unified model for the G1/S cell cycle transition. Nucleic Acids Res. (2020) 48:12483–501. doi: 10.1093/NAR/GKAA1002

  • 93

    GoelSDeCristoMJMcAllisterSSZhaoJJ. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. (2018) 28:911–25. doi: 10.1016/J.TCB.2018.07.002

  • 94

    HarbourJWLuoRXDei SantiAPostigoAADeanDC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. (1999) 98:859–69. doi: 10.1016/S0092-8674(00)81519-6

  • 95

    OttoTSicinskiP. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. (2017) 17:93–115. doi: 10.1038/NRC.2016.138

  • 96

    BeaverJAAmiri-KordestaniLCharlabRChenWPalmbyTTilleyAet al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. (2015) 21:4760–6. doi: 10.1158/1078-0432.CCR-15-1185

  • 97

    EdelmanMJRedmanMWAlbainKSMcGaryECRafiqueNMPetroDet al. SWOG S1400C (NCT02154490)-A phase II study of palbociclib for previously treated cell cycle gene alteration-positive patients with stage IV squamous cell lung cancer (Lung-MAP substudy). J Thorac Oncol. (2019) 14:1853–9. doi: 10.1016/J.JTHO.2019.06.027

  • 98

    GoldmanJWMazieresJBarlesiFDragnevKHKoczywasMGöskelTet al. A randomized phase III study of abemaciclib versus erlotinib in patients with stage IV non-small cell lung cancer with a detectable KRAS mutation who failed prior platinum-based therapy: JUNIPER. Front Oncol. (2020) 10:578756. doi: 10.3389/FONC.2020.578756

  • 99

    ZhangJXuDZhouYZhuZYangX. Mechanisms and implications of CDK4/6 inhibitors for the treatment of NSCLC. Front Oncol. (2021) 11:676041. doi: 10.3389/FONC.2021.676041

  • 100

    ElkamhawyALuQNadaHWooJQuanGLeeK. The journey of DDR1 and DDR2 kinase inhibitors as rising stars in the fight against cancer. Int J Mol Sci. (2021) 22. doi: 10.3390/IJMS22126535

  • 101

    WalshLANawshadAMediciD. Discoidin domain receptor 2 is a critical regulator of epithelial-mesenchymal transition. Matrix Biol. (2011) 30:243–7. doi: 10.1016/J.MATBIO.2011.03.007

  • 102

    FuHLValiathanRRArkwrightRSohailAMihaiCKumarasiriMet al. Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. J Biol Chem. (2013) 288:7430–7. doi: 10.1074/JBC.R112.444158

  • 103

    HammermanPSSosMLRamosAHXuCDuttAZhouWet al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery. (2011) 1:78–89. doi: 10.1158/2159-8274.CD-11-0005

  • 104

    RicordelCLespagnolALlamas-GutierrezFde TayracMKerjouanMFievetAet al. Mutational landscape of DDR2 gene in lung squamous cell carcinoma using next-generation sequencing. Clin Lung Cancer. (2018) 19:163–169.e4. doi: 10.1016/J.CLLC.2017.10.006

  • 105

    MiaoLWangYZhuSShiMLiYDingJet al. Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients. BMC Cancer. (2014) 14:1–10. doi: 10.1186/1471-2407-14-369

  • 106

    SasakiHShitaraMYokotaKOkudaKHikosakaYMoriyamaSet al. DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients. Oncol Lett. (2012) 4:33–7. doi: 10.3892/OL.2012.684

  • 107

    DayEWatersBSpiegelKAlnadafTManleyPWBuchdungerEet al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol. (2008) 599:44–53. doi: 10.1016/J.EJPHAR.2008.10.014

  • 108

    BrunnerAMCostaDBHeistRSGarciaELindemanNIShollLMet al. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung. J Thorac Oncol. (2013) 8:1434–7. doi: 10.1097/JTO.0B013E3182A47162

  • 109

    BeauchampEMWoodsBADulakAMTanLXuCGrayNSet al. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss. Mol Cancer Ther. (2014) 13:475–82. doi: 10.1158/1535-7163.MCT-13-0817

  • 110

    PayneLSHuangPH. Discoidin domain receptor 2 signaling networks and therapy in lung cancer. J Thorac Oncol. (2014) 9:900–4. doi: 10.1097/JTO.0000000000000164

  • 111

    LiWTianWYuanGDengPSenguptaDChengZet al. Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases. Nature. (2021) 590:498–503. doi: 10.1038/s41586-020-03069-8

  • 112

    XiongQZhouYZhangSZhangYXuYYangYet al. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer. Cancer Med. (2023) 12:10961–78. doi: 10.1002/cam4.5774

  • 113

    TopchuIPangeniRPBychkovIMillerSAIzumchenkoEYuJet al. The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors. Cell Mol Life Sci. (2022) 79:285. doi: 10.1007/s00018-022-04321-2

  • 114

    YuanGFloresNMHausmannSLofgrenSMKharchenkoVAngulo-IbanezMet al. Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature. (2021) 590:504–8. doi: 10.1038/s41586-020-03170-y

  • 115

    VoutsadakisIA. Characteristics and prognosis of 8p11.23-amplified squamous lung carcinomas. J Clin Med. (2023) 12. doi: 10.3390/JCM12051711

  • 116

    XuDLiuSWuXMartiTMDornPSchmidRAet al. Dissecting the immunological profiles in NSD3-amplified LUSC through integrative multi-scale analyses. Cancers (Basel). (2022) 14. doi: 10.3390/CANCERS14204997

  • 117

    HusmannDGozaniO. Histone lysine methyltransferases in biology and disease. Nat Struct Mol Biol. (2019) 26:880–9. doi: 10.1038/s41594-019-0298-7

  • 118

    ShresthaAKimNLeeSJJeonYHSongJJAnHet al. Targeting the nuclear receptor-binding SET domain family of histone lysine methyltransferases for cancer therapy: recent progress and perspectives. J Med Chem. (2021) 64:14913–29. doi: 10.1021/ACS.JMEDCHEM.1C01116

  • 119

    XiuSChiXJiaZShiCZhangXLiQet al. NSD3: Advances in cancer therapeutic potential and inhibitors research. Eur J Med Chem. (2023) 256:115440. doi: 10.1016/j.ejmech.2023.115440

  • 120

    BöttcherJDilworthDReiserUNeumüllerRASchleicherMPetronczkiMet al. Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3. Nat Chem Biol. (2019) 15:822–9. doi: 10.1038/S41589-019-0310-X

  • 121

    NuñezYVeraSBaezaVGonzalez-PecchiV. NSD3 in cancer: unraveling methyltransferase-dependent and isoform-specific functions. Int J Mol Sci. (2024) 25. doi: 10.3390/IJMS25020944

  • 122

    RaoRCDouY. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer. (2015) 15:334–46. doi: 10.1038/NRC3929

  • 123

    FroimchukEJangYGeK. Histone H3 lysine 4 methyltransferase KMT2D. Gene. (2017) 627:337–42. doi: 10.1016/J.GENE.2017.06.056

  • 124

    WeinsteinJNCollissonEAMillsGBShawKRMOzenbergerBAEllrottKet al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. (2013) 45:1113–20. doi: 10.1038/NG.2764

  • 125

    ZhangJDominguez-SolaDHusseinSLeeJEHolmesABBansalMet al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. (2015) 21:1190–8. doi: 10.1038/NM.3940

  • 126

    ToskaEOsmanbeyogluHUCastelPChanCHendricksonRCElkabetsMet al. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science. (2017) 355:1324–30. doi: 10.1126/SCIENCE.AAH6893

  • 127

    FangZWuXXiaoLWangCZhaoYZhangQet al. Somatic KMT2D loss-of-function mutations in lung squamous cell carcinoma: a single-center cohort study. J Thorac Dis. (2024) 16:3338–49. doi: 10.21037/JTD-24-134/COIF

  • 128

    HillmanRTCelestinoJTerranovaCBeirdHCGumbsCLittleLet al. KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary. Nat Commun. (2018) 9. doi: 10.1038/S41467-018-04950-X

  • 129

    Ortega-MolinaABossIWCanelaAPanHJiangYZhaoCet al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med. (2015) 21:1199–208. doi: 10.1038/NM.3943

  • 130

    XiongWDengZTangYDengZLiM. Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer. Biochem Biophys Res Commun. (2018) 504:129–36. doi: 10.1016/J.BBRC.2018.08.143

  • 131

    PanYHanHHuHWangHSongYHaoYet al. KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. Cancer Cell. (2023) 41:88–105.e8. doi: 10.1016/J.CCELL.2022.11.015

  • 132

    AlamHTangMMaitituohetiMDharSSKumarMHanCYet al. KMT2D deficiency impairs super-enhancers to confer a glycolytic vulnerability in lung cancer. Cancer Cell. (2020) 37:599–617.e7. doi: 10.1016/J.CCELL.2020.03.005

  • 133

    BattinoMGiampieriFPistollatoFSuredaAde OliveiraMRPittalàVet al. Nrf2 as regulator of innate immunity: A molecular Swiss army knife! Biotechnol Adv. (2018) 36:358–70. doi: 10.1016/j.bioteChadv.2017.12.012

  • 134

    LinLWuQLuFLeiJZhouYLiuYet al. Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers. Front Oncol. (2023) 13:1184079. doi: 10.3389/FONC.2023.1184079

  • 135

    TianJWangXShiHWuHWangCLiuNet al. Sestrin2/Keap1/Nrf2 pathway regulates mucus hypersecretion in pulmonary epithelium induced by traffic-related PM2.5 and water-soluble extracts. Ecotoxicol Environ Saf. (2023) 264:115455. doi: 10.1016/j.ecoenv.2023.115455

  • 136

    Baumel-AlterzonSKatzLSBrillGJean-PierreCLiYTseIet al. Nrf2 regulates β-cell mass by suppressing β-cell death and promoting β-cell proliferation. Diabetes. (2022) 71:989–1011. doi: 10.2337/db21-0581

  • 137

    PillaiRHayashiMZavitsanouA-MPapagiannakopoulosT. NRF2: KEAPing tumors protected. Cancer Discovery. (2022) 12:625–43. doi: 10.1158/2159-8290.CD-21-0922

  • 138

    KoEKimDMinDWKwonS-HLeeJ-Y. Nrf2 regulates cell motility through RhoA-ROCK1 signalling in non-small-cell lung cancer cells. Sci Rep. (2021) 11:1247. doi: 10.1038/s41598-021-81021-0

  • 139

    Sánchez-OrtegaMGarridoACirauquiCSanz-GonzalezLHernándezMCGonzález-GarcíaAet al. A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma. Redox Biol. (2024) 75. doi: 10.1016/J.REDOX.2024.103305

  • 140

    ZhangBMaZTanBLinN. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung. Expert Opin Ther Targets. (2019) 23:241–50. doi: 10.1080/14728222.2019.1559824

  • 141

    DempkeWCMReckM. KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype? Lung Cancer. (2021) 159:10–7. doi: 10.1016/j.lungcan.2021.07.006

  • 142

    WangXLiuZZhangLYangZChenXLuoJet al. Targeting deubiquitinase USP28 for cancer therapy. Cell Death Dis. (2018) 9. doi: 10.1038/S41419-017-0208-Z

  • 143

    CaoCVasilatosSNBhargavaRFineJLOesterreichSDavidsonNEet al. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression. Oncogene. (2017) 36:133–45. doi: 10.1038/ONC.2016.186

  • 144

    WangZSongQXueJZhaoYQinS. Ubiquitin-specific protease 28 is overexpressed in human glioblastomas and contributes to glioma tumorigenicity by regulating MYC expression. Exp Biol Med (Maywood). (2016) 241:255–64. doi: 10.1177/1535370215595468

  • 145

    DiefenbacherMEPopovNBlakeSMSchülein-VölkCNyeESpencer-DeneBet al. The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer. J Clin Invest. (2014) 124:3407–18. doi: 10.1172/JCI73733

  • 146

    PopovNWanzelMMadiredjoMZhangDBeijersbergenRBernardsRet al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol. (2007) 9:765–74. doi: 10.1038/NCB1601

  • 147

    Josue RuizEPinto-FernandezATurnbullAPLanLCharltonTMScottHCet al. USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma. Elife. (2021) 10. doi: 10.7554/ELIFE.71596

  • 148

    GuerraBRecioCAranda-TavíoHGuerra-RodríguezMGarcía-CastellanoJMFernández-PérezL. The mevalonate pathway, a metabolic target in cancer therapy. Front Oncol. (2021) 11:626971. doi: 10.3389/FONC.2021.626971

  • 149

    ChengCGengFChengXGuoD. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (Lond). (2018) 38:1–14. doi: 10.1186/S40880-018-0301-4

  • 150

    MaierCRHartmannOPrieto-GarciaCAl-ShamiKMSchlickerLVogelFCEet al. USP28 controls SREBP2 and the mevalonate pathway to drive tumour growth in squamous cancer. Cell Death Differ. (2023) 30:1710–25. doi: 10.1038/S41418-023-01173-6

  • 151

    CoulthardLRWhiteDEJonesDLMcDermottMFBurchillSA. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med. (2009) 15:369–79. doi: 10.1016/J.MOLMED.2009.06.005

  • 152

    LeeSRauchJKolchW. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci. (2020) 21. doi: 10.3390/IJMS21031102

  • 153

    DoladoISwatAAjenjoNDe VitaGCuadradoANebredaAR. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell. (2007) 11:191–205. doi: 10.1016/J.CCR.2006.12.013

  • 154

    IgeaANebredaAR. The stress kinase p38α as a target for cancer therapy. Cancer Res. (2015) 75:3997–4002. doi: 10.1158/0008-5472.CAN-15-0173

  • 155

    Martínez-LimónAJoaquinMCaballeroMPosasFde NadalE. The p38 pathway: from biology to cancer therapy. Int J Mol Sci. (2020) 21. doi: 10.3390/IJMS21061913

  • 156

    YeungYTYinSLuBFanSYangRBaiRet al. Losmapimod overcomes gefitinib resistance in non-small cell lung cancer by preventing tetraploidization. EBioMedicine. (2018) 28:51–61. doi: 10.1016/J.EBIOM.2018.01.017

  • 157

    ZarczynskaIGorska-ArciszMCortezAJKujawaKAWilkAMSkladanowskiACet al. p38 mediates resistance to FGFR inhibition in non-small cell lung cancer. Cells. (2021) 10. doi: 10.3390/CELLS10123363

  • 158

    LiRZengLZhaoHDengJPanLZhangSet al. ATXN2-mediated translation of TNFR1 promotes esophageal squamous cell carcinoma via m6A-dependent manner. Mol Ther. (2022) 30:1089–103. doi: 10.1016/J.YMTHE.2022.01.006

  • 159

    DondelingerYDardingMBertrandMJMWalczakH. Poly-ubiquitination in TNFR1-mediated necroptosis. Cell Mol Life Sci. (2016) 73:2165–76. doi: 10.1007/S00018-016-2191-4

  • 160

    MorganMJLiuZG. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. (2011) 21:103–15. doi: 10.1038/CR.2010.178

  • 161

    HaydenMSGhoshS. Shared principles in NF-kappaB signaling. Cell. (2008) 132:344–62. doi: 10.1016/J.CELL.2008.01.020

  • 162

    XiaoZShiGXiSSinghAKWillette-BrownJLiXet al. A TNFR1-UBCH10 axis drives lung squamous cell carcinoma dedifferentiation and metastasis through a cell-autonomous signaling loop. Cell Death Dis. (2022) 13. doi: 10.1038/S41419-022-05308-4

  • 163

    ChanTAYarchoanMJaffeeESwantonCQuezadaSAStenzingerAet al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. (2019) 30:44–56. doi: 10.1093/annonc/mdy495

  • 164

    SamsteinRMLeeC-HShoushtariANHellmannMDShenRJanjigianYYet al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. (2019) 51:202–6. doi: 10.1038/s41588-018-0312-8

  • 165

    LiMGaoXWangX. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data. Front Immunol. (2023) 14:1090838. doi: 10.3389/fimmu.2023.1090838

  • 166

    OkkenhaugKGrauperaMVanhaesebroeckB. Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis, and immunotherapy. Cancer Discovery. (2016) 6:1090–105. doi: 10.1158/2159-8290.CD-16-0716

  • 167

    ChandrasekaranSFunkCRKleberTPaulosCMShanmugamMWallerEK. Strategies to overcome failures in T-cell immunotherapies by targeting PI3K-δ and -γ. Front Immunol. (2021) 12:718621. doi: 10.3389/fimmu.2021.718621

  • 168

    WangLChenKWengSXuHRenYChengQet al. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma. World J Surg Oncol. (2023) 21:72. doi: 10.1186/s12957-023-02938-6

  • 169

    LiuCZhengSJinRWangXWangFZangRet al. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. (2020) 470:95–105. doi: 10.1016/J.CANLET.2019.10.027

  • 170

    SeegobinKMajeedUWiestNManochakianRLouYZhaoY. Immunotherapy in non-small cell lung cancer with actionable mutations other than EGFR. Front Oncol. (2021) 11:750657. doi: 10.3389/FONC.2021.750657

  • 171

    SunLHsuMCohenRBLangerCJMamtaniRAggarwalC. Association between KRAS variant status and outcomes with first-line immune checkpoint inhibitor-based therapy in patients with advanced non-small-cell lung cancer. JAMA Oncol. (2021) 7:937–9. doi: 10.1001/JAMAONCOL.2021.0546

  • 172

    HecklerMAliLRClancy-ThompsonEQiangLVentreKSLenehanPet al. Inhibition of CDK4/6 promotes CD8 T-cell memory formation. Cancer Discovery. (2021) 11:2564–81. doi: 10.1158/2159-8290.CD-20-1540

  • 173

    DengJWangESJenkinsRWLiSDriesRYatesKet al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discovery. (2018) 8:216–33. doi: 10.1158/2159-8290.CD-17-0915

  • 174

    ZhangQFLiJJiangKWangRGeJLYangHet al. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Theranostics. (2020) 10:10619–33. doi: 10.7150/THNO.44871

  • 175

    NohJYLeeIPHanNRKimMMinYKLeeSYet al. Additive effect of CD73 inhibitor in colorectal cancer treatment with CDK4/6 inhibitor through regulation of PD-L1. Cell Mol Gastroenterol Hepatol. (2022) 14:769–88. doi: 10.1016/J.JCMGH.2022.07.005

  • 176

    BairdLTaguchiKZhangATakahashiYSuzukiTKenslerTWet al. A NRF2-induced secretory phenotype activates immune surveillance to remove irreparably damaged cells. Redox Biol. (2023) 66:102845. doi: 10.1016/j.redox.2023.102845

  • 177

    XuKMaJHallSRRPengR-WYangHYaoF. Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks. Theranostics. (2023) 13:704–23. doi: 10.7150/thno.80184

  • 178

    LeoneRDZhaoLEnglertJMSunI-MOhM-HSunI-Het al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. (2019) 366:1013–21. doi: 10.1126/science.aav2588

  • 179

    XueWWuKGuoXChenCHuangTLiLet al. The pan-cancer landscape of glutamate and glutamine metabolism: A comprehensive bioinformatic analysis across 32 solid cancer types. Biochim Biophys Acta Mol Basis Dis. (2024) 1870. doi: 10.1016/J.BBADIS.2023.166982

  • 180

    ByunJ-KParkMLeeSYunJWLeeJKimJSet al. Inhibition of glutamine utilization synergizes with immune checkpoint inhibitor to promote antitumor immunity. Mol Cell. (2020) 80:592–606.e8. doi: 10.1016/j.molcel.2020.10.015

  • 181

    LiX. Emerging role of mutations in epigenetic regulators including MLL2 derived from The Cancer Genome Atlas for cervical cancer. BMC Cancer. (2017) 17:1–11. doi: 10.1186/S12885-017-3257-X

  • 182

    ShiYLeiYLiuLZhangSWangWZhaoJet al. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Cancer Med. (2021) 10:2216–31. doi: 10.1002/CAM4.3649

  • 183

    AminRBrazaMS. The follicular lymphoma epigenome regulates its microenvironment. J Exp Clin Cancer Res. (2022) 41. doi: 10.1186/S13046-021-02234-9

  • 184

    BaoXLiQChenJChenDYeCDaiXet al. Molecular subgroups of intrahepatic cholangiocarcinoma discovered by single-cell RNA sequencing-assisted multiomics analysis. Cancer Immunol Res. (2022) 10:811–28. doi: 10.1158/2326-6066.CIR-21-1101

  • 185

    WangGChowRDZhuLBaiZYeLZhangFet al. CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade. Cancer Discovery. (2020) 10:1912–33. doi: 10.1158/2159-8290.CD-19-1448

  • 186

    FangBWeiYPanJZhangTYeDZhuY. The somatic mutational landscape of mismatch repair deficient prostate cancer. J Clin Med. (2023) 12. doi: 10.3390/JCM12020623

  • 187

    LiuRNiuYLiuCZhangXZhangJShiMet al. Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer. Cancer Sci. (2023) 114:1229–39. doi: 10.1111/CAS.15716

  • 188

    ZhaoLLuoTJiangJWuJZhangX. Eight gene mutation-based polygenic hazard score as a potential predictor for immune checkpoint inhibitor therapy outcome in metastatic melanoma. Front Mol Biosci. (2022) 9:1001792. doi: 10.3389/FMOLB.2022.1001792

  • 189

    PokhrelRHAcharyaSAhnJHGuYPanditMKimJOet al. AMPK promotes antitumor immunity by downregulating PD-1 in regulatory T cells via the HMGCR/p38 signaling pathway. Mol Cancer. (2021) 20:1–15. doi: 10.1186/S12943-021-01420-9

  • 190

    LuYZhangMWangSHongBWangZLiHet al. p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nat Commun. (2014) 5. doi: 10.1038/NCOMMS5229

  • 191

    HensonSMMacaulayRRiddellNENunnCJAkbarAN. Blockade of PD-1 or p38 MAP kinase signaling enhances senescent human CD8(+) T-cell proliferation by distinct pathways. Eur J Immunol. (2015) 45:1441–51. doi: 10.1002/EJI.201445312

  • 192

    LiuXWuXCaoSHarringtonSMYinPMansfieldASet al. B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells. Sci Rep. (2016) 6. doi: 10.1038/SREP36722

  • 193

    XiaWQiXLiMWuYSunLFanXet al. Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner. Oncoimmunology. (2021) 10. doi: 10.1080/2162402X.2021.1995999

  • 194

    ZhangCZhangGSunNZhangZZhangZLuoYet al. Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma. EBioMedicine. (2020) 59. doi: 10.1016/J.EBIOM.2020.102959

  • 195

    BertrandFMontfortAMarcheteauEImbertCGilhodesJFilleronTet al. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. (2017) 8. doi: 10.1038/S41467-017-02358-7

  • 196

    YangYSunMYaoWWangFLiXWangWet al. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib. J Immunother Cancer. (2020) 8. doi: 10.1136/JITC-2019-000317

  • 197

    BenootTPiccioniEDe RidderKGoyvaertsC. TNFα and immune checkpoint inhibition: friend or foe for lung cancer? Int J Mol Sci. (2021) 22. doi: 10.3390/IJMS22168691

  • 198

    Müller-HermelinkNBraumüllerHPichlerBWiederTMailhammerRSchaakKet al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell. (2008) 13:507–18. doi: 10.1016/J.CCR.2008.04.001

  • 199

    YueSLiYChenXWangJLiMChenYet al. FGFR-TKI resistance in cancer: current status and perspectives. J Hematol Oncol. (2021) 14:23. doi: 10.1186/s13045-021-01040-2

  • 200

    ZhouYWuCLuGHuZChenQDuX. FGF/FGFR signaling pathway involved resistance in various cancer types. J Cancer. (2020) 11:2000–7. doi: 10.7150/JCA.40531

  • 201

    BockornyBRusanMChenWLiaoRGLiYPiccioniFet al. RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade. Mol Cancer Ther. (2018) 17:1526–39. doi: 10.1158/1535-7163.MCT-17-0464

  • 202

    JohannessenCMBoehmJSKimSYThomasSRWardwellLJohnsonLAet al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. (2010) 468:968–72. doi: 10.1038/nature09627

  • 203

    LeXAntonyRRazaviPTreacyDJLuoFGhandiMet al. Systematic functional characterization of resistance to PI3K inhibition in breast cancer. Cancer Discovery. (2016) 6:1134–47. doi: 10.1158/2159-8290.CD-16-0305

  • 204

    KimS-MKimHYunMRKangHNPyoK-HParkHJet al. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis. (2016) 5:e241. doi: 10.1038/oncsis.2016.48

  • 205

    HeJHuangZHanLGongYXieC. Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review). Int J Oncol. (2021) 59:1–20. doi: 10.3892/ijo.2021.5270

  • 206

    TeraiHSoejimaKYasudaHNakayamaSHamamotoJAraiDet al. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res. (2013) 11:759–67. doi: 10.1158/1541-7786.MCR-12-0652

  • 207

    KimTMSongAKimDWKimSAhnYOKeamBet al. Mechanisms of acquired resistance to AZD9291: A mutation-selective, irreversible EGFR inhibitor. J Thorac Oncol. (2015) 10:1736–44. doi: 10.1097/JTO.0000000000000688

  • 208

    WareKEHinzTKKleczkoESingletonKRMarekLAHelfrichBAet al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. (2013) 2:e39. doi: 10.1038/oncsis.2013.4

  • 209

    YangYQiuRWengQXuZSongJZhaoSet al. MLL4 regulates the progression of non-small-cell lung cancer by regulating the PI3K/AKT/SOX2 axis. Cancer Res Treat. (2023) 55:778–803. doi: 10.4143/CRT.2022.1042

  • 210

    ToskaECastelPChhangawalaSArruabarrena-AristorenaAChanCHristidisVCet al. PI3K inhibition activates SGK1 via a feedback loop to promote chromatin-based regulation of ER-dependent gene expression. Cell Rep. (2019) 27:294–306.e5. doi: 10.1016/J.CELREP.2019.02.111

  • 211

    JonesRBFarhiJAdamsMParwaniKKCooperGWZecevicMet al. Targeting MLL methyltransferases enhances the antitumor effects of PI3K inhibition in hormone receptor-positive breast cancer. Cancer Res Commun. (2022) 2:1569–78. doi: 10.1158/2767-9764.CRC-22-0158

  • 212

    KorenSBentires-AljM. Tackling resistance to PI3K inhibition by targeting the epigenome. Cancer Cell. (2017) 31:616–8. doi: 10.1016/J.CCELL.2017.04.010

  • 213

    DenisenkoTVBudkevichINZhivotovskyB. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. (2018) 9. doi: 10.1038/S41419-017-0063-Y

  • 214

    ZhangCMeiWZengC. Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities. Biochim Biophys Acta Rev Cancer. (2022) 1877. doi: 10.1016/J.BBCAN.2022.188707

  • 215

    CampbellJDAlexandrovAKimJWalaJBergerAHPedamalluCSet al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. (2016) 48:607–16. doi: 10.1038/NG.3564

  • 216

    IwasakiTShirotaHSasakiKOuchiKNakayamaYOshikiriHet al. Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study. Cancer Sci. (2024). doi: 10.1111/CAS.16355

  • 217

    YokoyamaYEstokTMWildR. Sirpiglenastat (DRP-104) induces antitumor efficacy through direct, broad antagonism of glutamine metabolism and stimulation of the innate and adaptive immune systems. Mol Cancer Ther. (2022) 21:1561–72. doi: 10.1158/1535-7163.MCT-22-0282

  • 218

    AllevatoMMTrinhSKoshizukaKNachmansonDNguyenTTCYokoyamaYet al. A genome-wide CRISPR screen reveals that antagonism of glutamine metabolism sensitizes head and neck squamous cell carcinoma to ferroptotic cell death. Cancer Lett. (2024) 598. doi: 10.1016/J.CANLET.2024.217089

  • 219

    KozonoDHuaXWuMCTolbaKAWaqarSNDragnevKHet al. Lung-MAP next-generation sequencing analysis of advanced squamous cell lung cancers (SWOG S1400). J Thorac Oncol. (2024). doi: 10.1016/J.JTHO.2024.07.024

  • 220

    ZhangYSunQLiangYYangXWangHSongSet al. FAM20A: a potential diagnostic biomarker for lung squamous cell carcinoma. Front Immunol. (2024) 15:1424197. doi: 10.3389/FIMMU.2024.1424197

  • 221

    WangCZhangJWangHChenRLuM. Family with sequence similarity 83, member A (FAM83A) inhibits ferroptosis via the Wnt/β-catenin pathway in lung squamous cell cancer. Cell Death Discovery. (2024) 10. doi: 10.1038/S41420-024-02101-4

  • 222

    JinNGeorgeTLOttersonGAVerschraegenCWenHCarboneDet al. Advances in epigenetic therapeutics with focus on solid tumors. Clin Epigenet. (2021) 13:1–27. doi: 10.1186/S13148-021-01069-7

  • 223

    StrainingREighmyW. Tazemetostat: EZH2 inhibitor. J Adv Pract Oncol. (2022) 13:158–63. doi: 10.6004/JADPRO.2022.13.2.7

  • 224

    YangPQiaoYMengMZhouQ. Cancer/testis antigens as biomarker and target for the diagnosis, prognosis, and therapy of lung cancer. Front Oncol. (2022) 12:864159. doi: 10.3389/FONC.2022.864159

  • 225

    HikmetFRassyMBackmanMMéarLMattssonJSMDjureinovicDet al. Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer. Mol Oncol. (2023) 17:2603–17. doi: 10.1002/1878-0261.13474

  • 226

    YehSJChangCALiCWWangLHCChenBS. Comparing progression molecular mechanisms between lung adenocarcinoma and lung squamous cell carcinoma based on genetic and epigenetic networks: big data mining and genome-wide systems identification. Oncotarget. (2019) 10:3760–806. doi: 10.18632/ONCOTARGET.26940

  • 227

    WangJElkriefAGuoWShuklaNGounderMLadanyiM. Prospects for epigenetic targeted therapies of bone and soft-tissue sarcomas. Sarcoma. (2021) 2021. doi: 10.1155/2021/5575444

  • 228

    BabarQSaeedATabishTAPriclSTownleyHThoratN. Novel epigenetic therapeutic strategies and targets in cancer. Biochim Biophys Acta Mol Basis Dis. (2022) 1868. doi: 10.1016/J.BBADIS.2022.166552

  • 229

    MorelDJefferyDAspeslaghSAlmouzniGPostel-VinayS. Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise. Nat Rev Clin Oncol. (2020) 17:91–107. doi: 10.1038/S41571-019-0267-4

  • 230

    ChengYHeCWangMMaXMoFYangSet al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. (2019) 4. doi: 10.1038/S41392-019-0095-0

  • 231

    RobertiAValdesAFTorrecillasRFragaMFFernandezAF. Epigenetics in cancer therapy and nanomedicine. Clin Epigenet. (2019) 11:1–18. doi: 10.1186/S13148-019-0675-4

  • 232

    BosePGandhiVKonoplevaM. Pathways and mechanisms of venetoclax resistance. Leuk Lymphoma. (2017) 58:2026–39. doi: 10.1080/10428194.2017.1283032

  • 233

    TsaoTShiYKornblauSLuHKonoplevSAntonyAet al. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells. Ann Hematol. (2012) 91:1861–70. doi: 10.1007/S00277-012-1537-8

  • 234

    DiNardoCDPratzKPullarkatVJonasBAArellanoMBeckerPSet al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. (2019) 133:7–17. doi: 10.1182/BLOOD-2018-08-868752

  • 235

    MerleGFriedlaenderADesaiAAddeoA. Antibody drug conjugates in lung cancer. Cancer J. (2022) 28:429–35. doi: 10.1097/PPO.0000000000000630

  • 236

    Gomes-da-SilvaLCKeppOKroemerG. Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death. Oncoimmunology. (2020) 9. doi: 10.1080/2162402X.2020.1841393

  • 237

    LiBTShenRBuonocoreDOlahZTNiAGinsbergMSet al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. (2018) 36:2532–7. doi: 10.1200/JCO.2018.77.9777

  • 238

    JännePABaikCSuWCJohnsonMLHayashiHNishioMet al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discovery. (2022) 12:74–89. doi: 10.1158/2159-8290.CD-21-0715

  • 239

    HeistRSGuarinoMJMastersGPurcellWTStarodubANHornLet al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-trop-2 drug conjugate, sacituzumab govitecan. J Clin Oncol. (2017) 35:2790–7. doi: 10.1200/JCO.2016.72.1894

  • 240

    WermkeMFelipEGambardellaVKubokiYMorgenszternDHamedZOet al. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Future Oncol. (2022) 18:2639–49. doi: 10.2217/FON-2022-0196

  • 241

    HaikalaHMLopezTKöhlerJEserPOXuMZengQet al. EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody-drug conjugate HER3-DXd. Cancer Res. (2022) 82:130–41. doi: 10.1158/0008-5472.CAN-21-2426

Summary

Keywords

lung squamous cell carcinoma, non-small-cell lung cancer, targeted therapies, immune microenvironment, multi-target combination

Citation

Chen Q, Zheng X, Cheng W and Li J (2024) Landscape of targeted therapies for lung squamous cell carcinoma. Front. Oncol. 14:1467898. doi: 10.3389/fonc.2024.1467898

Received

24 July 2024

Accepted

08 October 2024

Published

31 October 2024

Volume

14 - 2024

Edited by

Chun Wai Mai, UCSI University, Malaysia

Reviewed by

Savvas Lampridis, Imperial College London, United Kingdom

Qi Zhang, Houston Methodist Research Institute, United States

Updates

Copyright

© 2024 Chen, Zheng, Cheng and Li.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Weiting Cheng,

†These authors have contributed equally to this work and share first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Share on WeChat

Scan with WeChat to share this article

Article metrics